Lieber Jonathan I sold $10K of RLYB

Lieber Jonathan I (Chief Financial Officer) sold 599 shares of Rallybio Corp (RLYB) at $16.04 on 2026-10-27.

Original reporting
SEC EDGAR · Lieber Jonathan I
Published Oct 28, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RLYB
Bearish
medium confidence
Mentioned
$RLYB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLYBBearishLow
01

Why it matters

The CFO's modest sale is unlikely to move the stock significantly but adds to the flow of insider activity data.

02

Market read

Small insider sell; limited immediate trading impact.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: after-hours filing on 2026-10-28

Background

Form 4 filings provide primary disclosure of insider transactions, useful for assessing insider sentiment.

Company-level read

Ticker impact

$RLYBBearishMedium confidence
Context

CFO Lieber Jonathan I sold 599 shares for $9,608, a routine insider sale disclosed via Form 4.

Expected impact

likely slight downward pressure as market prices in the insider sale.

Evidence & confidence

The sale amount is small relative to holdings and market cap, but insider sells can signal negative sentiment.

Market effects

none

none

none

Counterpoint

The sale may be unrelated to company fundamentals and could be a routine liquidity move.

Key entities

  • Rallybio Corp

    Biotech company listed on US exchanges under ticker RLYB.

  • Lieber Jonathan I

    Chief Financial Officer of Rallybio Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RLYBHigh

Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

$RLYBHighAI 8/10

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av